Skip to content

IRIS- DESyne X2 in the IRIS-DES Registry

Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03588481
Acronym
IRIS DESyne X2
Enrollment
1000
Registered
2018-07-17
Start date
2018-11-28
Completion date
2031-12-31
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease, Coronary Occlusion, Coronary Stenosis

Keywords

PCI, DES, real world

Brief summary

This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.

Interventions

DEVICEDESyne X2

Novolimus-eluting stent

Sponsors

Seung-Jung Park
Lead SponsorOTHER
CardioVascular Research Foundation, Korea
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 19 and more * Intervention with DeSyne X2 drug-eluting coronary stent * Agreed with written informed consent form

Exclusion criteria

* Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock

Design outcomes

Primary

MeasureTime frameDescription
Composite event rate1yearDeath, non-fatal myocardial infarction, Target Vessel Revascularization

Secondary

MeasureTime frameDescription
All death5years
Cardiac death5years
Myocardial infarction5years
Composite event of death or myocardial infarction5years
Composite event of cardiac death or myocardial infarction5years
Target Vessel revascularization5years
Target Lesion revascularization5years
Stent thrombosis5yearsstent thrombosis as classified by an Academic Research Consortium
Stroke5years
Procedural success3daysdefined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.

Countries

South Korea

Contacts

CONTACTJung-hee Ham, RN
cvcrc5@amc.seoul.kr82230104728

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026